maple syrup urine disease
Metabolic · 2014–2023
No submission for this condition has carried consumer input, including the 7 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amino acid formula with vitamins and minerals without valine, leucine, isoleucine and supplemented with arachidonic acid and docosahexaenoic acid Dietary management of maple syrup urine disease (MSUD) in infants and young children from 6 months to 5 years of age. | Mar 2023 | Recommended with restriction | none received |
| amino acid formula with vitamins and minerals without valine, leucine and isoleucine Dietary management of Maple Syrup Urine Disease (MSUD) in patients aged 3 years or over. | Jul 2020 | Recommended with restriction | none received |
| amino acid formula with fat, carbohydrate, without valine, leucine and isoleucine Dietary management of maple syrup urine disease (MSUD). | Nov 2019 | Recommended with restriction | none received |
| Amino acid formula with vitamins and minerals without valine, leucine and isoleucine Dietary management of patients with maple syrup urine disease (MSUD), specifically for use as a second-stage protein supplement in patients aged 6 months to 5… | Nov 2019 | Recommended with restriction | none received |
| amino acid formula with vitamins and minerals Nutritional management of phenylketonuria (PKU), tyrosinaemia (TYR), and maple syrup urine disease (MSUD) in children. | Mar 2015 | Recommended | no section in document |
| amino acid formula with vitamins and minerals without valine, leucine and isoleucine Treatment of maple syrup urine disease (MSUD). | Jul 2014 | Recommended with restriction | no section in document |
| amino acid formula with vitamins and minerals without valine, leucine and isoleucine A nutritional formula for the dietary management of maple syrup urine disease (MSUD). | Nov 2014 | Deferred | no section in document |
What the PBS pays
$69M in government benefit over 2024–25, across 66,021 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amino acid formula with vitamins and minerals without valine, leucine, isoleucine, supplemented with arachidonic acid and docosahexaenoic acid | $19.5M |
| Amino acid formula with vitamins and minerals (three formulations: without phenylalanine; without phenylalanine and tyrosine; without valine, leucine and isoleucine) | $17.2M |
| amino acid formula with vitamins and minerals without valine, leucine and isoleucine | $17.1M |
| amino acid formula with fat, carbohydrate, without valine, leucine and isoleucine | $15.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.